前列腺特异性膜抗原(PSMA)靶向手术的德尔菲共识项目——来自国际多学科专家组的成果
该德尔菲共识通过两轮问卷(105条陈述,第二轮16条,回应率89%)汇集国际多学科专家意见,就PSMA靶向手术的PET/CT时机、示踪剂注射至手术间隔、淋巴结转移识别价值、优选引导技术及需随机对照试验等达成共识;手术切缘评估方面意见中立或不确定,高比例「无法回答」提示需进一步研究。
要点
- 诊断性PSMA配体PET/CT理想应在手术前<1个月完成,1-3个月可接受。
- 示踪剂注射与手术间隔16-20小时似乎更受青睐。
- PSMA靶向最有价值用于识别淋巴结转移,优选引导技术为γ、荧光和混合成像。
核心结论
- 该德尔菲共识为实施或开发PSMA靶向手术技术的临床医生和研究者提供指导。
- 最终共识应在被随机临床试验数据支持后方可纳入指南。
研究设计与样本
- 德尔菲共识项目,通过SurveyMonkey®分发105条陈述(9点Likert量表评分),随后进行第二轮评估共识(16条陈述,回应率89%)。
- 共识采用分歧指数定义,评估方法为研究与发展项目/加利福尼亚大学洛杉矶分校适宜性方法。
- 86名专家组成员参与(72.1%临床医生、8.1%产业界、15.1%科学家、4.7%其他),以泌尿外科背景为主(57.0%),其次为核医学(22.1%)。
主要发现
- 共识达成:诊断性PSMA配体PET/CT理想应在手术前<1个月进行,1-3个月可接受。
- 共识达成:示踪剂注射与手术间隔16-20小时似乎更受青睐。
- 共识达成:PSMA靶向最有价值用于识别淋巴结转移。
- 共识达成:γ、荧光和混合成像是优选的引导技术;需要随机对照临床试验确定肿瘤学价值。
- 关于手术切缘评估,对PSMA靶向手术价值的观点为中立或不确定;高比例「无法回答」回应表明需进一步研究以解决知识缺口(如切伦科夫或β发射)。
关键数值与推荐
- 诊断性PSMA配体PET/CT理想应在手术前<1个月进行,1-3个月可接受。
- 示踪剂注射与手术间隔16-20小时似乎更受青睐。
- PSMA靶向最有价值用于识别淋巴结转移。
- γ、荧光和混合成像是优选的引导技术。
- 需要随机对照临床试验确定肿瘤学价值。
临床怎么用
- 该共识为实施或开发PSMA靶向手术技术的临床医生和研究者提供指导。
- 最终共识应在被随机临床试验数据支持后方可纳入指南。
局限性
- 关于手术切缘评估,对PSMA靶向手术价值的观点为中立或不确定。
- 高比例「无法回答」回应表明需进一步研究以解决知识缺口(如切伦科夫或β发射)。
- 共识最终应在被随机临床试验数据支持后方可纳入指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) is increasingly considered as a molecular target to achieve precision surgery for prostate cancer. A Delphi consensus was conducted to explore expert views in this emerging field and to identify knowledge and evidence gaps as well as unmet research needs that may help change practice and improve oncological outcomes for patients. METHODS: One hundred and five statements (scored by a 9-point Likert scale) were distributed through SurveyMonkey®. Following evaluation, a consecutive second round was performed to evaluate consensus (16 statements; 89% response rate). Consensus was defined using the disagreement index, assessed by the research and development project/University of California, Los Angeles appropriateness method. RESULTS: Eighty-six panel participants (72.1% clinician, 8.1% industry, 15.1% scientists, and 4.7% other) participated, most with a urological background (57.0%), followed by nuclear medicine (22.1%). Consensus was obtained on the following: (1) The diagnostic PSMA-ligand PET/CT should ideally be taken < 1 month before surgery, 1-3 months is acceptable; (2) a 16-20-h interval between injection of the tracer and surgery seems to be preferred; (3) PSMA targeting is most valuable for identification of nodal metastases; (4) gamma, fluorescence, and hybrid imaging are the preferred guidance technologies; and (5) randomized controlled clinical trials are required to define oncological value. Regarding surgical margin assessment, the view on the value of PSMA-targeted surgery was neutral or inconclusive. A high rate of "cannot answer" responses indicates further study is necessary to address knowledge gaps (e.g., Cerenkov or beta-emissions). CONCLUSIONS: This Delphi consensus provides guidance for clinicians and researchers that implement or develop PSMA-targeted surgery technologies. Ultimately, however, the consensus should be backed by randomized clinical trial data before it may be implemented within the guidelines.
引用
- Berrens AC, Scheltema M, Maurer T, et al. Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel. Eur J Nucl Med Mol Imaging. 2023. PMID: 38012448. doi:10.1007/s00259-023-06524-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。